Parkinson's disease

[Journal of Cellular and Molecular Medicine] Researchers investigated whether co-grafting of MSCs could improve the survival and reinnervation ability of dopaminergic precursors transplanted in animal models of Parkinson's disease.

[Movement Disorders] The authors explore the opportunities and challenges resulting from the convergence of organoid high-throughput screening and AI-driven data analytics and outline potential future avenues toward the discovery of novel mechanisms and drugs in Parkinson's disease research.

[BlueRock Therapeutics LP] BlueRock Therapeutics LP announced that the US FDA has granted Fast Track designation for DA01 for advanced Parkinson’s disease. DA01, BlueRock’s PSC-derived dopaminergic neuron therapy, is under evaluation in a Phase I study.

[BlueRock Therapeutics LP] BlueRock Therapeutics LP announced that the US FDA has granted Fast Track designation for DA01 for advanced Parkinson’s disease. DA01, BlueRock’s PSC-derived dopaminergic neuron therapy, is under evaluation in a Phase I study.

[Journal of Bioscience and Bioengineering] Researchers evaluated changes in extracellular vesicles morphology, concentration, and miRNA and protein expression in culture supernatants during the differentiation of iPSCs into neural lineage cells, for application in regenerative medicine for Parkinson's disease.

[Stem Cell Reports] Scientists used isogenic human induced pluripotent stem cells (iPSCs) with and without PARK2 knockout to investigate the effect of parkin loss of function by comparative metabolomics supplemented with ultrastructural and functional analyses.